Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.

Saved in:
Bibliographic Details
Title: Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.
Authors: Huppert LA; Department of Medicine, University of California San Francisco, San Francisco, USA. Electronic address: Laura.huppert@ucsf.edu., Wolf D; Department of Laboratory Medicine, University of California San Francisco, San Francisco, USA., Yau C; Department of Surgery, University of California San Francisco, San Francisco, USA., Brown-Swigart L; Department of Laboratory Medicine, University of California San Francisco, San Francisco, USA., Hirst GL; Department of Surgery, University of California San Francisco, San Francisco, USA., Isaacs C; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA., Pusztai L; Yale School of Medicine, Yale University, New Haven, USA., Pohlmann PR; Department of Breast Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, USA., DeMichele A; Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA., Shatsky R; Division of Hematology/Oncology, University of California San Diego, San Diego, USA., Yee D; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, USA., Thomas A; Division of Hematology/Oncology, Duke Cancer Center, Durham, USA., Nanda R; Section of Hematology/Oncology, University of Chicago, Chicago, USA., Perlmutter J; I-SPY2 Research Advocate, Ann Arbor, USA., Heditsian D; I-SPY2 Research Advocate, Ann Arbor, USA., Hylton N; Department of Radiology, University of California San Francisco, San Francisco, USA., Symmans F; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, USA., Van't Veer LJ; Department of Laboratory Medicine, University of California San Francisco, San Francisco, USA., Esserman L; Department of Laboratory Medicine, University of California San Francisco, San Francisco, USA. Electronic address: https://twitter.com/DrLauraEsserman., Rugo HS; Department of Medicine, University of California San Francisco, San Francisco, USA. Electronic address: https://twitter.com/hoperugo.
Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2025 Feb; Vol. 36 (2), pp. 172-184. Date of Electronic Publication: 2024 Oct 28.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1569-8041
DOI:10.1016/j.annonc.2024.10.018